BOVIE MEDICAL CORPORATION Bovie Medical Corporation (NYSE:BVX), a maker of medical devices and supplies, and the developer of J-Plasma®, a patented new surgical product, today provided an update on recent developments for J-Plasma®.
The Company is pleased to announce that all J-Plasma® disposable hand pieces as well as the Bovie® Ultimate™ generator have received CE Mark approval for compliance with European Union safety, health and environmental protection requirements. As a result, the Company will be able to sell these devices in the 31 countries of the European Economic Area.
Also, the Company announced the December publication of a new white paper on J-Plasma®, authored by Dr. Craig E. McCoy of Women’s Wellness Center in Columbia, Missouri. The White Paper addresses the use of J-Plasma® in targeting the chronic pelvic pain of occult endometriosis sufferers compared with existing options including apparent lesion removal and the complete removal of the peritoneum. The white paper highlighted benefits of using J-Plasma®, including minimized lateral and depth of thermal spread, reduced healing times and reduced risk to vital structures such as the fallopian tubes and ovaries.
The white paper is available on Bovie Medical’s website, www.boviemedical.com.
In addition, the Company today announced the appointment of Ms. Stephanie Van Skike as Western US Regional Sales Manager, effective December 31, 2014. Ms. Van Skike has more than 20 years of experience in sales. Most recently, she held the position of Southwest Regional Sales Manager for TEI Biosciences Inc. Prior to that, she held positions at companies including LifeCell Corp. and Novartis Pharmaceuticals AG. Ms. Van Skike holds an MBA from the University of Phoenix, as well as a B.A. from the California State University. She will report to Todd Hornsby, Vice President of Sales.
Ms. Van Skike has been awarded non-qualified stock options to purchase 20,000 shares of common stock, exercisable at the closing price as of today, January 12, 2015. The options shall vest and be exercisable in four equal annual installments beginning on the first anniversary of the effective date.
“I am pleased to announce these important new developments for J-Plasma®, where we continue to make progress with commercialization. The CE Mark approval for the J-Plasma® hand pieces and the Bovie® Ultimate™ generator gives us access to important European markets, adding a new audience of potential users for our plasma technology, and will help speed registration in other foreign markets,” said Robert L. Gershon, chief executive officer of Bovie Medical. “The appointment of Stephanie Van Skike demonstrates our ability to attract world-class personnel for our sales team, while the latest white paper, the fifth published in 2014, is further independent verification of J-Plasma®’s competitive advantages.”
“We look forward to keeping the market up-to-date as we continue the commercialization of J-Plasma® throughout 2015,” Mr. Gershon concluded.
About Bovie Medical Corporation
Bovie Medical Corporation is a leading maker of medical devices and supplies, as well as the developer of J-Plasma®, a patented new plasma-based surgical product for cutting and coagulation. J-Plasma® utilizes a helium ionization process to produce a stable, focused beam of ionized gas that provides surgeons with greater precision, minimal thermal spread and an absence of conductive currents through the patient during surgery. Bovie Medical Corporation is also a leader in the manufacture of a range of electrosurgical products and technologies, marketed through both private labels and the Company’s own well-respected brands (Bovie®, Aaron®, IDS™ and ICON™) to distributors worldwide. The Company also leverages its expertise through original equipment manufacturing (OEM) agreements with other medical device manufacturers. For further information about the Company’s current and new products, please refer to the Investor Relations section of Bovie Medical Corporation’s website www.boviemed.com.
Cautionary Statement on Forward-Looking Statements
Certain matters discussed in this release and oral statements made from time to time by representatives of the Company may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Although the Company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions, it can give no assurance that its expectations will be achieved. Forward-looking information is subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected. Many of these factors are beyond the Company’s ability to control or predict. Important factors that may cause actual results to differ materially and that could impact the Company and the statements contained in this release can be found in the Company’s filings with the Securities and Exchange Commission including the Company’s Reports on Forms 10-K/A and 10-Qs for the year ended December 31, 2013 and the quarters ended March 31, 2014, June 30, 2014 and September 30, 2014. For forward-looking statements in this release, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The Company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise.
